Details

Autor(en) / Beteiligte

• Hoerauf, Hans
• Feltgen, Nicolas
• Weiss, Claudia
• Paulus, Eva-Maria
• Schmitz-Valckenberg, Steffen
• Pielen, Amelie
• Puri, Pankaj
• Berk, Hüsnü
• Eter, Nicole
• Wiedemann, Peter
• Lang, Gabriele E
• Rehak, Matus
• Wolf, Armin
• Bertelmann, Thomas
• Hattenbach, Lars-Olof

Titel

Reply

Ist Teil von

• American journal of ophthalmology, 2016-09, Vol.169, p.292

Ort / Verlag

Chicago: Elsevier Limited

Erscheinungsjahr

2016

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [...]the given letter reduction between months 12 and 24 in this subgroup of the original trial cohort with an unknown selection bias cannot be judged as a significant visual loss in a heterogenous disease such as CRVO with a possibility of conversion to ischemia in 34% within 3 years.3 Thirty-two patients with CRVO were included in the RETAIN study and data were available for 28 patients 4 years after the CRUISE baseline study.4 A total of 53.1% of these patients treated with ranibizumab gained 15 letters or more, which in our opinion is excellent.